Biao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Biao Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Yanming Wu
Department of Cardiology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou Ninth People’s Hospital, 215000 Suzhou, Jiangsu, China
5 shared publicationsGang Chen
Department of Critical Care Medicine, The Affiliated Suzhou Municipal Hospital, Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China
2 shared publicationsJiping Xue
Department of Critical Care Medicine, The Affiliated Suzhou Municipal Hospital, Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China
2 shared publicationsWanglu Bian
Department of Cardiology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou Ninth People's Hospital , Suzhou
2 shared publicationsYifei Cao
Department of Critical Care Medicine, The Affiliated Suzhou Municipal Hospital, Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China
2 shared publications- Yunfu Wu
Department of Critical Care Medicine, Suzhou Municipal Hospital, China
2 shared publications
Latest Publications
- 8 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Acute Inferior Myocardial Infarction with Anomalous Origin of the Right Coronary Artery, Myocardial Bridging and Fibro‐Lipid Plaque
We describe a 35‐year‐old male patient who had acute inferior myocardial infarction based on clinical signs and electrocardiographic abnormalities after experiencing sudden chest pain for 2 h. An abnormal origin of the right coronary artery (RCA) from the left coronary sinus was discovered by emergency coronary angiography, along with mild stenosis in the mid‐RCA segment that persisted even after intracoronary nitroglycerin was administered. The mid‐RCA lesion was identified by intravascular ultrasonography (IVUS) as a 48% stenotic fibro‐lipid plaque with a lipid core and thin fibrous top. A minimum luminal diameter of 2.14 mm was found at the deformed RCA ostium with concomitant myocardial bridging. The patient experienced total symptom alleviation and an uneventful recovery after receiving dual antiplatelet therapy, intense lipid‐lowering treatment, diltiazem for myocardial bridging, and stringent risk factor control. For long‐term risk reduction, a multidisciplinary evaluation is planned for surgical of the coronary abnormality. In addition to highlighting the significance of tailored management approaches for congenital coronary anomalies combined with acquired vulnerable plaques, this case underscores the crucial role of multimodality imaging, particularly IVUS, in accurate etiological diagnosis and treatment decision‐making for young patients with acute myocardial infarction (AMI) caused by complex coronary lesions.
- 8 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Acute Inferior Myocardial Infarction with Anomalous Origin of the Right Coronary Artery, Myocardial Bridging and Fibro‐Lipid Plaque
We describe a 35‐year‐old male patient who had acute inferior myocardial infarction based on clinical signs and electrocardiographic abnormalities after experiencing sudden chest pain for 2 h. An abnormal origin of the right coronary artery (RCA) from the left coronary sinus was discovered by emergency coronary angiography, along with mild stenosis in the mid‐RCA segment that persisted even after intracoronary nitroglycerin was administered. The mid‐RCA lesion was identified by intravascular ultrasonography (IVUS) as a 48% stenotic fibro‐lipid plaque with a lipid core and thin fibrous top. A minimum luminal diameter of 2.14 mm was found at the deformed RCA ostium with concomitant myocardial bridging. The patient experienced total symptom alleviation and an uneventful recovery after receiving dual antiplatelet therapy, intense lipid‐lowering treatment, diltiazem for myocardial bridging, and stringent risk factor control. For long‐term risk reduction, a multidisciplinary evaluation is planned for surgical of the coronary abnormality. In addition to highlighting the significance of tailored management approaches for congenital coronary anomalies combined with acquired vulnerable plaques, this case underscores the crucial role of multimodality imaging, particularly IVUS, in accurate etiological diagnosis and treatment decision‐making for young patients with acute myocardial infarction (AMI) caused by complex coronary lesions.
- Open Access
- 24 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
New Insights into Cardiac Intensive Care
In recent years, there have been significant advances in both theoretical knowledge and technological applications in cardiac intensive care, a crucial area of cardiovascular medicine. This study methodically outlines the most recent developments in the field’s research, including new understandings of pathophysiological mechanisms, advancements in monitoring technology, improvements to prognostic evaluation systems, and optimization of therapeutic approaches. The article emphasizes cutting-edge advancements like artificial intelligence-assisted decision-making systems, microcirculation monitoring tools, and precision medicine approaches, which are customized to individual patient needs by combining evidence from basic research and clinical practice. Precision medicine in the cardiac intensive care unit (CICU) is described in this review as a reactive, patient-centered approach that uses real-time clinical, molecular, imaging, and hemodynamic data to customize acute therapeutic and monitoring interventions for critically ill cardiac patients with complicated, frequently multi-organ pathophysiology. Despite tremendous advancements, there are still difficulties in ensuring individualized care and converting these developments into standardized clinical procedures. In order to promote the development of standardized therapy and customized medical practice in this developing field, this thorough overview attempts to provide researchers and doctors with up-to-date information on cardiac intensive care.
- 24 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
Open AccessNew Insights into Cardiac Intensive Care
In recent years, there have been significant advances in both theoretical knowledge and technological applications in cardiac intensive care, a crucial area of cardiovascular medicine. This study methodically outlines the most recent developments in the field’s research, including new understandings of pathophysiological mechanisms, advancements in monitoring technology, improvements to prognostic evaluation systems, and optimization of therapeutic approaches. The article emphasizes cutting-edge advancements like artificial intelligence-assisted decision-making systems, microcirculation monitoring tools, and precision medicine approaches, which are customized to individual patient needs by combining evidence from basic research and clinical practice. Precision medicine in the cardiac intensive care unit (CICU) is described in this review as a reactive, patient-centered approach that uses real-time clinical, molecular, imaging, and hemodynamic data to customize acute therapeutic and monitoring interventions for critically ill cardiac patients with complicated, frequently multi-organ pathophysiology. Despite tremendous advancements, there are still difficulties in ensuring individualized care and converting these developments into standardized clinical procedures. In order to promote the development of standardized therapy and customized medical practice in this developing field, this thorough overview attempts to provide researchers and doctors with up-to-date information on cardiac intensive care.
- 17 June 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 437, 133532
Letter to the editor: “Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit”
- 17 June 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 437, 133532
Letter to the editor: “Performance evaluation of four scoring systems for mortality prediction in a contemporary cardiac intensive care unit”
- Open Access
- 2 June 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2605-2607
Insights into the Interconnection of Sarcopenia in Heart Failure
- 2 June 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2605-2607
Open AccessInsights into the Interconnection of Sarcopenia in Heart Failure
- Open Access
- 12 March 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 3189-3190
Correspondence with the Editor About the Article ‘Clinical Implication of Sarcopenia in Patients with Acute Decompensated Heart Failure: Design and Rationale’
- 12 March 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 3189-3190
Open AccessCorrespondence with the Editor About the Article ‘Clinical Implication of Sarcopenia in Patients with Acute Decompensated Heart Failure: Design and Rationale’
- Open Access
- 12 December 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (5) , 3408-3409
Myocardial infarction associated with myocardial bridging: A case report
- 12 December 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (5) , 3408-3409
Open AccessMyocardial infarction associated with myocardial bridging: A case report
- Open Access
- 11 February 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (3) , 832-837
CD8 + T‐cell percentage increases in diffuse large B‐cell lymphoma patients receiving mannatide combined with standard regimens
What is known and objective Suppression of antilymphoma effector cells, mainly T cells, is a key prerequisite for tumorigenesis and resistance in diffuse large B‐cell lymphoma (DLBCL). The aim of the study was to determine whether mannatide (MT), an immunomodulator, could enhance the immunological response in DLBCL patients receiving standard regimens. Methods Patients with aggressive DLBCL treated with first‐line standard regimens were included in this single‐centre retrospective study. T‐cell subtypes were detected using flow cytometry before and after the first cycle of treatment. Patients in MT group were treated with MT combined with standard first‐line regimens, and patients in control group with standard first‐line regimens. Chi‐square test or Fisher's exact tests were used for categorical variables and independent t‐tests for continuous variables. Results and discussion Among the 138 DLBCL patients enrolled in this study, 34 (24.64%) were assigned to the MT group, while 104 (75.36%) patients were included in the control group. There were no significant differences in clinicopathological characteristics and baseline T‐cell subtypes between the two groups (p > 0.05). After treatment, CD3+CD8+ T‐cell percentage of MT group was significantly higher than that of control group (p = 0.01), while CD3+CD4+ T‐cell percentage of MT group was significantly lower than that of control group (p < 0.01). Thus, the CD4+/CD8+ ratio of MT group was significantly lower than that of control group (p = 0.03). In the subgroup of DLBCL patients treated with EPOCH/R‐EPOCH, significant differences were also found in post‐treatment CD3+CD8+ T‐cell percentage (p < 0.01), CD3+CD4+ T‐cell percentage (p = 0.02) and CD4+/CD8+ ratio (p = 0.01) between MT and control groups. What is new and conclusion CD3+CD8+ T‐cell percentage increased in DLBCL patients receiving MT treatment. Further studies are required to determine the clinical benefits of MT.
- 11 February 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (3) , 832-837
Open AccessCD8 + T‐cell percentage increases in diffuse large B‐cell lymphoma patients receiving mannatide combined with standard regimens
What is known and objective Suppression of antilymphoma effector cells, mainly T cells, is a key prerequisite for tumorigenesis and resistance in diffuse large B‐cell lymphoma (DLBCL). The aim of the study was to determine whether mannatide (MT), an immunomodulator, could enhance the immunological response in DLBCL patients receiving standard regimens. Methods Patients with aggressive DLBCL treated with first‐line standard regimens were included in this single‐centre retrospective study. T‐cell subtypes were detected using flow cytometry before and after the first cycle of treatment. Patients in MT group were treated with MT combined with standard first‐line regimens, and patients in control group with standard first‐line regimens. Chi‐square test or Fisher's exact tests were used for categorical variables and independent t‐tests for continuous variables. Results and discussion Among the 138 DLBCL patients enrolled in this study, 34 (24.64%) were assigned to the MT group, while 104 (75.36%) patients were included in the control group. There were no significant differences in clinicopathological characteristics and baseline T‐cell subtypes between the two groups (p > 0.05). After treatment, CD3+CD8+ T‐cell percentage of MT group was significantly higher than that of control group (p = 0.01), while CD3+CD4+ T‐cell percentage of MT group was significantly lower than that of control group (p < 0.01). Thus, the CD4+/CD8+ ratio of MT group was significantly lower than that of control group (p = 0.03). In the subgroup of DLBCL patients treated with EPOCH/R‐EPOCH, significant differences were also found in post‐treatment CD3+CD8+ T‐cell percentage (p < 0.01), CD3+CD4+ T‐cell percentage (p = 0.02) and CD4+/CD8+ ratio (p = 0.01) between MT and control groups. What is new and conclusion CD3+CD8+ T‐cell percentage increased in DLBCL patients receiving MT treatment. Further studies are required to determine the clinical benefits of MT.
- 1 September 2015
- Published by Wolters Kluwer Health in Shock
- Vol. 44 (3) , 234-238
Increased Neutrophil Gelatinase–Associated Lipocalin is Associated with Mortality and Multiple Organ Dysfunction Syndrome in Severe Sepsis and Septic Shock
Background: This study examines the clinical utility of increased neutrophil gelatinase–associated lipocalin (NGAL) as an indicator of mortality and multiple organ dysfunction syndrome (MODS) in severe sepsis and septic shock. Methods: We designed a prospective cohort study in an intensive care unit, and 123 patients with severe sepsis or septic shock were included. Data were used to determine a relationship between NGAL and the development of MODS and mortality. These associations were determined by the Mann-Whitney U test, log-rank test, Cox proportional hazards regression analyses, and plotting the receiver operating characteristic curve. Results: Patients with high NGAL (75th percentile) had increased risk of mortality and MODS compared with patients with low NGAL (log-rank test, P < 0.05). There were 39 patients (32%) with mortality during follow-up at 12 months, 10 patients (8%) with MODS on day 1, and 37 patients (30%) on day 7. The area under the receiver operating characteristic curve showed that high NGAL could predict mortality (0.6385) during intensive care unit stay. After adjustment for confounding risk factors chosen by backward elimination by Cox regression analysis, high NGAL remained an independent predictor of mortality and MODS (hazard ratios, 2.128 [95% confidence interval, 1.078–4.203; P = 0.030] and 1.896 [95% confidence interval, 1.012–3.552; P = 0.046], respectively). Conclusions: High plasma NGAL independently predicts mortality and MODS in severe sepsis and septic shock.
- 1 September 2015
- Published by Wolters Kluwer Health in Shock
- Vol. 44 (3) , 234-238
Increased Neutrophil Gelatinase–Associated Lipocalin is Associated with Mortality and Multiple Organ Dysfunction Syndrome in Severe Sepsis and Septic Shock
Background: This study examines the clinical utility of increased neutrophil gelatinase–associated lipocalin (NGAL) as an indicator of mortality and multiple organ dysfunction syndrome (MODS) in severe sepsis and septic shock. Methods: We designed a prospective cohort study in an intensive care unit, and 123 patients with severe sepsis or septic shock were included. Data were used to determine a relationship between NGAL and the development of MODS and mortality. These associations were determined by the Mann-Whitney U test, log-rank test, Cox proportional hazards regression analyses, and plotting the receiver operating characteristic curve. Results: Patients with high NGAL (75th percentile) had increased risk of mortality and MODS compared with patients with low NGAL (log-rank test, P < 0.05). There were 39 patients (32%) with mortality during follow-up at 12 months, 10 patients (8%) with MODS on day 1, and 37 patients (30%) on day 7. The area under the receiver operating characteristic curve showed that high NGAL could predict mortality (0.6385) during intensive care unit stay. After adjustment for confounding risk factors chosen by backward elimination by Cox regression analysis, high NGAL remained an independent predictor of mortality and MODS (hazard ratios, 2.128 [95% confidence interval, 1.078–4.203; P = 0.030] and 1.896 [95% confidence interval, 1.012–3.552; P = 0.046], respectively). Conclusions: High plasma NGAL independently predicts mortality and MODS in severe sepsis and septic shock.
- 1 April 2015
- Published by Elsevier in Journal of Critical Care
- Vol. 30 (2) , 271-275
Correlation of lactate/albumin ratio level to organ failure and mortality in severe sepsis and septic shock
- 1 April 2015
- Published by Elsevier in Journal of Critical Care
- Vol. 30 (2) , 271-275
Correlation of lactate/albumin ratio level to organ failure and mortality in severe sepsis and septic shock